Abstract P657: Soluble Receptor for Advanced Glycation End Products and Subtypes Are Protective Biomarkers of Functional Outcome but Not Those of Recurrence in Acute Ischemic Stroke

Stroke ◽  
2021 ◽  
Vol 52 (Suppl_1) ◽  
Author(s):  
Chunjuan Wang ◽  
Yuesong Pan ◽  
Zixiao Li ◽  
Xia Meng ◽  
Hao Li ◽  
...  
Keyword(s):  
Ischemic Stroke ◽  
Acute Ischemic Stroke ◽  
Advanced Glycation End Products ◽  
Plasma Levels ◽  
Unfavorable Outcome ◽  
Stroke Recurrence ◽  
Advanced Glycation ◽  
Stroke Patients ◽  
Glycation End Products ◽  
End Products

Background and purpose: Soluble isoforms of receptor for advanced glycation end products (sRAGE) and subtypes have been recognized as contradictory biomarkers of ischemic stroke. We sought to investigate whether the plasma levels of sRAGE and subtypes can predict unfavorable outcome and recurrence in acute ischemic stroke patients. Methods: The data used in this study was from the Third China National Stroke Registy (CNSR III), which was a nationwide, prospective cohort study to register acute ischemic stroke and transient ischemic attack patients. Plasma levels of sRAGE and subtypes were tested by enzyme-linked immunoabsorbent assay (ELISA) method and demonstrated by quartiles. Cox proportional hazards model was used to analysis the association of sRAGE and subtypes with unfavorable outcomes or stroke recurrence at 3- and 12-month in acute ischemic stroke patients, respectively. Unfavorable outcome was defined as modified Rankin Scale (mRS) 3-6. Results: Three thousand one hundred and eighty-nine acute ischemic stroke patients were included and tested for plasma level of sRAGE and subtypes (cRAGE and esRAGE) in this study. Mean age was 62.8±11.5 years and 2161 (67.8%) were male. At 3- and 12-month, there were 426 (13.5%) and 409 (13.1%) patients with an unfavorable outcome and 185 (5.9%) and 293 (9.2%) patients with stroke recurrence, respectively. Refered by quartile one of sAGRE, the adjusted hazard ratios (aHRs) and 95% confidence intervals (95% CIs) of unfavorable outcomes in quartile two to four were 0.81 (0.59-1.10), 0.66 (0.48-0.92) and 0.65 (0.47-0.91) at 3-month and 0.79 (0.58-1.08), 0.61 (9.44-0.85) and 0.66 (0.48-0.91) at 12-month; those of stroke recurrence in quartile two to four were 0.99 (0.66-1.49), 0.99 (0.66-1.49) and 1.02 (0.68-1.54) at 3-month and 1.05 (0.76-1.45), 0.95 (0.68-1.32) and 1.07 (0.77-1.48) at 12-month, respectively. Same data trends were found in subtypes cRAGE and esRAGE. Conclusion: Plasma levels of sRAGE and subtypes were protective biomarkers of unfavorable outcomes but not those of stroke recurrence in acute ischemic stroke patients.

scholarly journals Receptor for Advanced Glycation End Products Is Involved in LPA5-Mediated Brain Damage after a Transient Ischemic Stroke

Life ◽  
2021 ◽  
Vol 11 (2) ◽  
pp. 80
Author(s):  
Arjun Sapkota ◽  
Sung Jean Park ◽  
Ji Woong Choi
Keyword(s):  
Ischemic Stroke ◽  
Advanced Glycation End Products ◽  
Brain Injuries ◽  
Artery Occlusion ◽  
Advanced Glycation ◽  
Ischemic Brain ◽  
Blood Brain Barrier Disruption ◽  
Glycation End Products ◽  
End Products ◽  
Ischemic Core

Lysophosphatidic acid receptor 5 (LPA5) has been recently identified as a novel pathogenic factor for brain ischemic stroke. However, its underlying mechanisms remain unclear. Here, we determined whether the receptor for advanced glycation end products (RAGE) could be involved in LPA5-mediated brain injuries after ischemic challenge using a mouse model of transient middle cerebral artery occlusion (tMCAO). RAGE was upregulated in the penumbra and ischemic core regions after tMCAO challenge. RAGE upregulation was greater at 3 days than that at 1 day after tMCAO challenge. It was mostly observed in Iba1-immunopositive cells of a post-ischemic brain. Suppressing LPA5 activity with its antagonist, TCLPA5, attenuated RAGE upregulation in the penumbra and ischemic core regions, particularly on Iba1-immunopositive cells, of injured brains after tMCAO challenge. It also attenuated blood–brain barrier disruption, one of the core pathogenesis upon RAGE activation, after tMCAO challenge. As an underlying signaling pathways, LPA5 could contribute to the activation of ERK1/2 and NF-κB in injured brains after tMCAO challenge. Collectively, the current study suggests that RAGE is a possible mediator for LPA5-dependent ischemic brain injury.

scholarly journals Plasma Levels of Soluble Receptor for Advanced Glycation End Products and Coronary Atherosclerosis: Possible Correlation with Clinical Presentation

2013 ◽  
Vol 35 ◽  
pp. 135-140 ◽  
Author(s):  
Colomba Falcone ◽  
Sara Bozzini ◽  
Angela D’Angelo ◽  
Benedetta Matrone ◽  
Anna Colonna ◽  
...  
Keyword(s):  
Coronary Artery Disease ◽  
Coronary Artery ◽  
Unstable Angina ◽  
Advanced Glycation End Products ◽  
Stable Angina ◽  
Plasma Levels ◽  
Advanced Glycation ◽  
Glycation End Products ◽  
End Products ◽  
Artery Disease

Receptor for Advanced Glycation End-products (RAGE) is a multi-ligand receptor ubiquitous present on epithelial, neuronal, vascular and inflammatory cells, usually expressed at low levels in homeostasis and to increased degrees at sites of stress or injury. The aim of the present study was to evaluate sRAGE plasma levels in patients with Acute Coronary Syndrome (ACS) and to assess its diagnostic efficacy in identification of patients with acute events. Plasma levels of sRAGE were determined in 860 patients with Coronary Artery Disease (CAD): 530 patients presented stable angina and 330 were observed during acute ischemic event (147 with unstable angina and 183 with myocardial infarction). sRAGE plasma levels were significantly lower in patients with ACS than in patients with stable angina: [median 584 pg/mL (IQR: 266–851 pg/mL) in MI patients, median 769 pg/mL (IQR: 394–987 pg/mL) in patients with unstable angina, median 834 pg/mL (IQR 630–1005 pg/mL) in patients with stable angina;P<0.001]. sRAGE levels did not differ among ACS patients stratified by the extent of coronary artery disease. In conclusion, this study confirm the role of sRAGE in activation and progression of inflammatory process and suggests the possibility that sRAGE can be considered an indicator of destabilization of vulnerable plaque.

Plasma levels of advanced glycation end products in healthy, long-term vegetarians and subjects on a western mixed diet

2001 ◽  
Vol 40 (6) ◽  
pp. 275-281 ◽  
Author(s):  
Katarína Šebeková ◽  
Marica Krajčovičová ◽  
Reinhard Schinzel ◽  
Veronika Faist ◽  
Jana Klvanová ◽  
...  
Keyword(s):  
Advanced Glycation End Products ◽  
Plasma Levels ◽  
Mixed Diet ◽  
Advanced Glycation ◽  
Glycation End Products ◽  
End Products
Sign in / Sign up

Export Citation Format

Share Document